文献速递脑血管病癫痫神经重症与神经感染

疑似缺血性卒中伴起病癫痫的静脉溶栓预后分析

Intravenous thrombolysis for suspected ischemic stroke with seizure at onset.
PubMed 文献 · Ann Neurol · 2019-09-09

这项多中心IVT登记研究纳入10,074例接受静脉溶栓的疑似缺血性卒中患者,其中146例(1.5%)伴起病癫痫。未校正分析中起病癫痫患者预后较差,但经校正、匹配及加权分析后,起病癫痫与症状性颅内出血、3个月死亡及功能预后均无独立关联。

要点

  • 起病癫痫不是静脉溶栓后不良预后的独立预测因素。
  • 疑似缺血性卒中伴起病癫痫不应成为拒绝静脉溶栓的理由。
  • 结论在最终诊断为缺血性卒中或卒中模拟病的患者中一致。

核心结论

  • 起病癫痫并非静脉溶栓后不良预后的独立预测因素,据此不给疑似缺血性卒中患者溶栓似乎不合理。

研究设计与样本

  • 多中心静脉溶栓登记研究,纳入10,074例接受静脉溶栓的疑似缺血性卒中患者,其中146例(1.5%)伴起病癫痫。

主要发现

  • 起病癫痫患者入院时NIHSS评分和血糖显著更高,女性、既往卒中及既往功能依赖比例更高。
  • 未校正分析中起病癫痫患者预后普遍较差。
  • 校正、匹配及加权分析后,起病癫痫与症状性颅内出血、死亡及功能预后的关联均消失。
  • 症状性颅内出血未校正OR=1.53(95%CI 0.74-3.14),校正OR=0.52(95%CI 0.13-2.16),匹配OR=0.68(95%CI 0.15-3.03),加权OR=0.95(95%CI 0.39-2.32)。
  • 结论在最终诊断为缺血性卒中(89/146)或卒中模拟病(57/146)的患者中一致。

关键数值与推荐

  • 症状性颅内出血采用欧洲急性卒中协作研究II定义。
  • 功能预后采用改良Rankin量表评估,包括mRS≥3和序贯mRS分析。

临床怎么用

  • 对疑似缺血性卒中且起病时伴癫痫的患者,不应仅因起病癫痫而拒绝静脉溶栓。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Seizure at onset (SaO) has been considered a relative contraindication for intravenous thrombolysis (IVT) in patients with acute ischemic stroke, although this appraisal is not evidence based. Here, we investigated the prognostic significance of SaO in patients treated with IVT for suspected ischemic stroke. METHODS: In this multicenter, IVT-registry-based study we assessed the association between SaO and symptomatic intracranial hemorrhage (sICH, European Cooperative Acute Stroke Study II definition), 3-month mortality, and 3-month functional outcome on the modified Rankin Scale (mRS) using unadjusted and adjusted logistic regression, coarsened exact matching, and inverse probability weighted analyses. RESULTS: Among 10,074 IVT-treated patients, 146 (1.5%) had SaO. SaO patients had significantly higher National Institutes of Health Stroke Scale score and glucose on admission, and more often female sex, prior stroke, and prior functional dependence than non-SaO patients. In unadjusted analysis, they had generally less favorable outcomes. After controlling for confounders in adjusted, matched, and weighted analyses, all associations between SaO and any of the outcomes disappeared, including sICH (odds ratio [OR]unadjusted = 1.53 [95% confidence interval (CI) = 0.74-3.14], ORadjusted = 0.52 [95% CI = 0.13-2.16], ORmatched = 0.68 [95% CI = 0.15-3.03], ORweighted = 0.95 [95% CI = 0.39-2.32]), mortality (ORunadjusted = 1.49 [95% CI = 1.00-2.24], ORadjusted = 0.98 [95% CI = 0.5-1.92], ORmatched = 1.13 [95% CI = 0.55-2.33], ORweighted = 1.17 [95% CI = 0.73-1.88]), and functional outcome (mRS ≥ 3/ordinal mRS: ORunadjusted = 1.33 [95% CI = 0.96-1.84]/1.35 [95% CI = 1.01-1.81], ORadjusted = 0.78 [95% CI = 0.45-1.32]/0.78 [95% CI = 0.52-1.16], ORmatched = 0.75 [95% CI = 0.43-1.32]/0.45 [95% CI = 0.10-2.06], ORweighted = 0.87 [95% CI = 0.57-1.34]/1.00 [95% CI = 0.66-1.52]). These results were consistent regardless of whether patients had an eventual diagnosis of ischemic stroke (89/146) or stroke mimic (57/146 SaO patients). INTERPRETATION: SaO was not an independent predictor of poor prognosis. Withholding IVT from patients with assumed ischemic stroke presenting with SaO seems unjustified. ANN NEUROL 2019;86:770-779.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Polymeris AA, Curtze S, Erdur H, et al. Intravenous thrombolysis for suspected ischemic stroke with seizure at onset. Ann Neurol. 2019. PMID: 31435960. doi:10.1002/ana.25582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。